



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/757,832	01/14/2004	Herbert W. Virgin	60005161-0168	5585
26263	7590	08/11/2005	EXAMINER	
SONNENSCHN NATH & ROSENTHAL LLP P.O. BOX 061080 WACKER DRIVE STATION, SEARS TOWER CHICAGO, IL 60606-1080			CHEN, STACY BROWN	
			ART UNIT	PAPER NUMBER
			1648	

DATE MAILED: 08/11/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/757,832

Applicant(s)

VIRGIN, HERBERT W.

Examiner

Stacy B. Chen

Art Unit

1648

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 14 January 2004.
- 2a) ☐ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-35 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☐ Claim(s) _____ is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☒ Claim(s) 1-35 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Election/Restrictions

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-5, 18-24 and 29-31, drawn to polynucleotide SEQ ID NO: 1 and its various fragments and complements, classified in class 536, subclass 23.1.
 - II. Claims 6-8, drawn to an amino acid sequence encoded by SEQ ID NO: 1, classified in class 530, subclass 300.
 - III. Claims 9-11, drawn to SEQ ID NO: 2, classified in class 530, subclass 300.
 - IV. Claims 12-14, drawn to SEQ ID NO: 3, classified in class 530, subclass 300.
 - V. Claims 15-17, drawn to SEQ ID NO: 4, classified in class 530, subclass 300.
 - VI. Claims 25-28, drawn to a method of detecting the presence of virus, classified in class 435, subclass 5.
 - VII. Claims 32-34, drawn to an antibody, classified in class 424, subclass 130.1.
 - Further restriction is required from claim 32. Applicant is required to elect one of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and the polypeptide encoded by SEQ ID NO: 1.
 - VIII. Claim 35, drawn to a method for identifying an agent capable of modulating or preventing virus infection, classified in class 435, subclass 5.
2. The inventions are distinct, each from the other because of the following reasons:
 - a) The polypeptides of Groups (II-V) and polynucleotide of Group I are patentably distinct inventions for the following reasons. Polypeptides, which are composed of amino acids,

Art Unit: 1648

and polynucleotides, which are composed of purine and pyrimidine units, are structurally distinct molecules; any relationship between a polynucleotide and polypeptide is dependent upon the information provided by the nucleic acid sequence open reading frame as it corresponds to the primary amino acid sequence of the encoded polypeptide. In the present claims, a polynucleotide of Group I does not necessarily encode a polypeptide of Group II, III, IV or V. For example, the polynucleotide of Group I includes polynucleotides that are 80% homologous to SEQ ID NO: 1, encoding a similar polypeptide, but not the same polypeptide. Similarly, some of the nucleic acid molecules of Group I are complementary to SEQ ID NO: 1, and therefore would not encode the polypeptide of Group II. Furthermore, the information provided by the polynucleotide of Group I can be used to make a materially different polypeptide than that of Group II. For example, a nucleic acid which hybridizes to SEQ ID NO: 1, even under highly stringent conditions, encompasses molecules which contain point mutations, splice sites, frameshift mutations or stop codons which would result in use of a different open reading frame, and thus encode a protein that lacks any significant structure in common with the polypeptide encoded by the exact sequence of SEQ ID NO: 1. In addition, while a polypeptide of Group II can be made by methods using some, but not all, of the polynucleotides that fall within the scope of Group I, it can also be recovered from a natural source using biochemical means. For instance, the polypeptide can be isolated using affinity chromatography. For these reasons, the inventions of Groups I and II are patentably distinct. Furthermore, searching the inventions of Groups I and II together would impose a serious search burden. In the instant case, the search of the polypeptides and the polynucleotides are not coextensive. The inventions of Groups I and II have a separate status in the art as shown by their different classifications. In cases such as this

Art Unit: 1648

one where descriptive sequence information is provided, the sequences are searched in appropriate databases. There is search burden also in the non-patent literature. Prior to the concomitant isolation and expression of the sequence of interest there may be journal articles devoted solely to polypeptides which would not have described the polynucleotide. Similarly, there may have been "classical" genetics papers which had no knowledge of the polypeptide but spoke to the gene. Searching, therefore is not coextensive. In addition, the polynucleotide claims include polynucleotides having 80% identity to the sequence identified. This search requires an extensive analysis of the art retrieved in a sequence search and will require an in-depth analysis of technical literature. The scope of polynucleotides as claimed extend beyond the polynucleotide that encodes the claimed polypeptides as explained above. As such, it would be burdensome to search the inventions of Groups I and II together.

b) The polypeptides of Groups II-V and the antibody of Group VII are patentably distinct for the following reasons. While the inventions of both Groups II-V and Group VII are polypeptides, in this instance the polypeptide of Group II is a single chain molecule that functions as an enzyme, whereas the polypeptide of Group VII encompasses antibodies including IgG which comprises 2 heavy and 2 light chains containing constant and variable regions, and including framework regions which act as a scaffold for the 6 complementarity determining regions (CDRs) that function to bind an epitope. Thus the polypeptides of Groups II-V and the antibody of Group VII are structurally distinct molecules; any relationship between the two is dependent upon the correlation between the scope of the polypeptides that the antibody binds and the scope of the antibodies that would be generated upon immunization with the polypeptide.

Art Unit: 1648

In this case, the polypeptides of Groups II-V are large molecules which contain potentially hundreds of regions to which an antibody may bind, whereas the antibody of Group VII is defined in terms of its binding specificity to a small structure within SEQ ID NO: 2-4 of a small structure within the polypeptide encoded by SEQ ID NO:1. An antibody of Group VII would not specifically bind all of the polypeptides of Groups II-V because the polypeptides of Groups II-V are not required to be identical sequences. Therefore the polypeptide and antibody are patentably distinct.

Furthermore, searching the inventions of Groups II-V and Group VII would impose a serious search burden. The inventions have a separate status in the art as shown by their different classifications. A polypeptide and an antibody which binds to the polypeptide require different searches. An amino acid sequence search of the full-length protein is necessary for a determination of novelty and unobviousness of the protein. However, such a search is not required to identify the antibodies of Group VII. Furthermore, antibodies which bind to an epitope of a polypeptide of Group II (or Groups III-V) may be known even if a polypeptide of Group II is novel. The technical literature search for the polypeptides of Groups II-V and the antibody of Group VII are not coextensive, e.g., antibodies may be characterized in the technical literature prior to discovery of or sequence of their binding target.

c) The polynucleotide of Group I and the antibody of Group VII are patentably distinct for the following reasons. The antibody of Group VII includes, for example, IgG molecules which comprise 2 heavy and 2 light chains containing constant and variable regions, and including framework regions which act as a scaffold for the 6 complementarity determining regions (CDRs). Polypeptides, such as the antibody of Group VII which are composed of amino

Art Unit: 1648

acids, and polynucleotides, which are composed of nucleic acids, are structurally distinct molecules; any relationship between a polynucleotide and polypeptide is dependent upon the information provided by the nucleic acid sequence open reading frame as it corresponds to the primary amino acid sequence of the encoded polypeptide. In the present claims, a polynucleotide of Group I will not encode an antibody of Group VII, and the antibody of Group VII cannot be encoded by a polynucleotide of Group I. Therefore the antibody and polynucleotide are patentably distinct. The antibody and polynucleotide inventions have a separate status in the art as shown by their different classifications. Furthermore, searching the inventions of Group I and Group VII would impose a serious search burden since a search of the polynucleotide of Group I would not be used to determine the patentability of an antibody of Group VII, and vice-versa.

d) Groups II-V are distinct polypeptides that do not share exact sequence identity. Since the amino acid sequences are different, the encoded polypeptides are different. Further, a search for each polypeptide would require a search through every sequence in every sequence database used by the PTO. Such a search would be a serious burden on the PTO resources. For these reasons, Applicant is required to elect one Group for examination.

e) Inventions I and VI are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product, a polynucleotide, can be used in a materially different process of using, such as inducing an immune response in a test animal.

Art Unit: 1648

f) Inventions (II-V, VII) and VI are unrelated because the method of Group VI does not require the polypeptides of Groups II-V or the antibody of Group VII. They are not disclosed as capable of use together.

g) Inventions (I-VII) and VIII are unrelated because the method of Group VIII does not require the polynucleotide of Group I, the polypeptides of Groups II-V, the antibody of Group VII, or the method of Group VI. None of these inventions are disclosed as capable of use with Group VIII.

Because these inventions are distinct for the reasons given above, have acquired a separate status in the art as shown by their different classification, and the search required for each Group is not required for the other Groups because each Group requires a different non-patent literature search due to each Group comprising different products and/or method steps, restriction for examination purposes as indicated is proper. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

3. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. **Process claims that depend from or otherwise include all the limitations of the patentable product** will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier.

Art Unit: 1648

Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai*, *In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.** Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.


Conclusion

4. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR

Art Unit: 1648

system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Stacy B. Chen whose telephone number is 571-272-0896. The examiner can normally be reached on M-F (7:00-4:30). If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James C. Housel can be reached on 571-272-0902. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

A handwritten signature in cursive script that reads "Stacy B. Chen".

Stacy B. Chen
August 9, 2005